Sat, Aug 23, 2014, 5:07 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

spook2b 156 posts  |  Last Activity: Aug 21, 2014 7:48 PM Member since: Jul 4, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • spook2b spook2b Aug 21, 2014 7:48 PM Flag

    This is from the nasdaq site:
    Institutional Ownership 73.65%
    133 Institutional Holders
    126,554,571 Total Shares Held

  • Reply to

    Cowen Reiterates Buy PT $9.90 EOM

    by pki58 Aug 19, 2014 8:11 AM
    spook2b spook2b Aug 19, 2014 9:15 PM Flag

    I'm guessing this was at least part of the reason for the run-up yesterday. Thanks for posting gogh, and thanks to pki for alerting us to the upgrade.

  • Reply to

    CNS royalty obligation

    by spook2b Aug 19, 2014 3:30 PM
    spook2b spook2b Aug 19, 2014 5:03 PM Flag

    Raph, here's a clip from my posting of the initial court docket 3 years & 1 week ago:

    08/10/2011 #1 COMPLAINT filed against Par Pharmaceutical Companies Inc., Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 0311-930038.) - filed by Avanir Pharmaceuticals Inc., Avanir Holding Company, {and the} Center for Neurologic Study.

    So, it appears to me that CNS was a party, along with AVNR, in the suit against Par. I'm guessing there was an agreement on sharing attorney costs.

  • Big for MLNK, that is. I'm seeing 55.9K at 4:12, and 1,500 at 4:25. That's fairly unusual for this stock. Perhaps we could see something develop here - one can only hope!

  • Between about 2:50 and 3:25, around 150K shares were sold and the pps went up about 6 cents. Not exactly earth-shattering, but notable in that MLNK has been languishing in the $3:60-3:80 range since late June. There was a triple top established at around $3.97, so a break there might imply a move up.

    I had a feeling that we might hear news on the acquisition front when the quarterly report was issued, but I forgot that this is the FOURTH fiscal quarter, and it will be an ANNUAL report. That means they have something like 70-75 days from the end of the fiscal year (July31), or that we may not see the report until Oct 10-15 (Oct 15 last year). In other words, we may not see any news here for almost 2 months. (sigh)

  • Reply to

    CNS royalty obligation

    by spook2b Aug 19, 2014 3:30 PM
    spook2b spook2b Aug 19, 2014 3:33 PM Flag

    It seems 2b saying that the company thinks the recent ANDA ruling MAY allow them to reduce or eliminate the royalty obligation. Considering that it is running at about $1.25M/quarter this may have an impact on the bottom line.

    Does anyone have any further knowledge or an opinion on this??

  • This is from the 10Q, page 20:

    Center for Neurologic Study (“CNS”) — The Company is party to an exclusive license agreement with CNS pursuant to which the Company licensed rights to certain patents relating to the use of DM/Q to treat neurological conditions.

    The Company paid to CNS a $75,000 milestone upon FDA approval of NUEDEXTA for the treatment of PBA in fiscal 2011. In addition, the Company has been obligated to pay CNS a royalty ranging from approximately 5% to 8% of net U.S. GAAP revenue generated by sales of NUEDEXTA. During the nine months ended June 30, 2014 and 2013, royalties of approximately $3.7 million and $2.5 million, respectively, were recorded to cost of product sales in the accompanying condensed consolidated statements of operations. Under certain circumstances, the Company may have the obligation to pay CNS a portion of net revenues received if the Company sublicenses the licensed patent rights to a third party.

    Under the agreement with CNS, the Company is required to make payments on achievements of up to a maximum of ten milestones, based upon five specific clinical indications. Maximum payments for these milestone payments could total approximately $1.1 million if the Company pursued the development of the licensed patent rights for all five of the licensed indications. In general, individual milestones range from $75,000 to $125,000 for each accepted NDA and a similar amount for each approved NDA in addition to the royalty discussed above on net U.S. GAAP revenues. The Company does not have the obligation to develop additional indications under the CNS license agreement.

    In light of the ANDA ruling on April 30, 2014, the Company is in the process of assessing the impact on the CNS royalty obligation. The Company recorded a royalty obligation for the nine months ended June 30, 2014. The Company may reduce or eliminate the royalty obligation, depending on the outcome of its assessment.

  • Reply to

    Getting word KK just purchased 50,000 shares.

    by avnrtwentyfve Aug 18, 2014 2:29 PM
    spook2b spook2b Aug 18, 2014 4:51 PM Flag

    This is the 8th month of the year, and I only count 3 occasion on which KK has sold this year, so "He sells every month!" is a bit of an overstatement.

  • I took a look at today's chart, and noticed a bump in volume while I was at lunch. It looks like it was from about 11:40 to 11:55 a.m., with a corresponding jump in the share price at about 11:55. I went to the time & sales site to check for big blocks, and this was the only really good-sized one:

    11:42:54 ..... $ 5.74 ..... 40,000

    The point & figure chart for AVNR continues to show a triple-top breakout with a preliminary price target of $10.25. Again, tech sites and analysis are just a small part of the whole picture - hopefully some of the news catalysts we've been waiting for will materialize to boost us to much higher levels.

    glta AVNR longs.

  • The nasdaq stock consultant has this on their AVNR site today:

    WATCH for possible breakout above 5.87, no resistance in area just above.
    Type: True breakout from Triple resistance. Target: 6.49, 13.3%


    Again, no guarantees, but some of these resistance areas are closely monitored.

  • They posted their 13F-HR while I was out for lunch. In Q1 they were listed as a new holder, buying 345,000 shares of AVNR. Considering the Q1 pps of AVNR, I think it's quite possible they booked a quick profit when the share price shot up in Q2. Irregardless, the total Q2 holdings of institutions will stay above 126M in Q2. I think this level of institutional sponsorship bodes well for AVNRs future, though today's runup is no doubt due in part to the overall jump in the market. According to the nasdaq site, we're nearing a potential breakout point - see next post.

  • Reply to

    Avanir's Abreva deal with Glaxo

    by yi71 Aug 16, 2014 2:01 PM
    spook2b spook2b Aug 17, 2014 12:15 AM Flag

    yi71, in an earlier post you said you have access to SEC filings. Get the 10Q filed on Aug8 this year, and look at page 26 under "Partnered Programs" and you'll find this:

    In November 2002, we sold to Drug Royalty USA an undivided interest in our right to receive future Abreva royalties under the GSK License Agreement for $24.1 million (the “Drug Royalty Agreement”). Under the Drug Royalty Agreement, Drug Royalty USA had the right to receive royalties from GSK on sales of Abreva until the expiration of the patent for Abreva on April 28, 2014. We retained the right to receive 50% of all royalties (a net of 4%) under the GSK License Agreement for annual net sales of Abreva in the U.S. and Canada in excess of $62.0 million through April 28, 2014. From the effective date of the GSK License Agreement up to the 2002 sale of our royalty rights to Drug Royalty USA, Inc., we received a total of approximately $5.9 million in royalty payments from GSK attributed to the 8% royalty on net sales by GSK. The GSK License Agreement expired in April 2014 and we do not expect any future revenues from royalties under this agreement.

    This information has also been imparted on several occasions in conference calls by management.

  • They're now showing the 1.1M-share add by Artal Group, and some more new holders.

    Updated total - 126,914,920 shares, or 73.86% of shares outstanding.

    Increased Positions 82 27,755,384
    Decreased Positions 39 5,351,582

    And here's a neat stat:

    New Positions -- 34 institutions bought 7,097,182 shares.
    Sold Out Positions -- 15 institutions sold 843,915.

    For some reason, NASDAQ still hasn't picked up the SAC Capital sell of 25,798 shares.

    Also, they're probably having the same problem I had with the SunTrust Banks report - totally scrambled, but I believe they've sold their 406,653-share position. That leaves only Creative Planning and Fiera Capital to report. Even if they both sold, along with the 406K SunTrust sale (I think), the total should remain above 126M shares - that's a very big jump in a one quarter period, tute-wise, adding something like 22M shares.

  • The last filing I saw from them showed 24,475,000 SONS shares on May 27. Their 13F filing today is showing 22,000,000.

    Regardless, institutional holdings of SONS increased in Q2 by about 3M shares if you factor in the Empire sale.

  • Reply to

    NAZ site has updated - tutes LOVE AVNR!

    by spook2b Aug 15, 2014 9:11 AM
    spook2b spook2b Aug 15, 2014 9:58 AM Flag

    Everyone thanks for the kind words. Makes this massive case of eyestrain worth it!

    I'm looking at the NAZ site and I see they still haven't got 9 reports. I've got all but 3. The most obvious one they're missing is Artal Group, which added 1.1M AVNR shares. Brown Bros. Harriman is still holding their 500 shares, while D.E. Shaw went from 22,646 to 30,900. Sunrise Partners appear to have sold out their 48,533 shares, and it looks like SunTrust Banks sold their 406,653 shares, though I can't be sure since their filing is pretty hard to filter.

    That leaves me with Creative Planning, Deutsche Bank, and Fiera Capital. I don't think the totals will change very much, but the Artal buy should push us up another half million shares or so (if SunTrust sold).

    At any rate, it appears to me that institutions are looking ahead and like what they see. Another factor may be that the massive buy by Baker Brothers attracted the attention of some of the new holders.

  • The NASDAQ site is showing the institutional holdings in AVNR have ballooned to 125,203,100 shares in Q2. To put that in perspective, remember that the Q1 total was 104.811M.

    We now have 131 institutional holders, as compared to 118 last Q.

    82 Increased Positions, adding 26,020,711 shares, while 37 Decreased Positions selling 6,338,028 shares.
    That's nearly 20 MILLION additional AVNR shares bought by institutions last quarter. The percentage of shares outstanding has increased to 72% from the low 60's.

  • 1,199,622 AVNR shares vs just 12, 494 last quarter. They also show 29,400 shares in Call options & 15,200 shares in Put options.

    There were only about 5 or 6 left on my list, the biggest being SunTrust Banks with 406,653 last Q and I didn't expect to see much change, but this adds yet another million shares to the tute total.

    I should mention Iguana is out showing they still hold 250K shares, while our friends at Orbimed remain on the sidelines after a brief return a few quarters ago.

    Breaking news - Artal is out showing 2,000,000 shares + 1,000,000 options!

    I'm thinking we may see the tute total go over 120M tomorrow. Should be interesting.

  • 18,558,487 shares of AVNR. That will bump the tute total by around 12.75M shares. Yippee

  • spook2b by spook2b Aug 14, 2014 4:20 PM Flag

    I saw their filings earlier, but double-checked to make sure. They are showing NO STOCK whatsoever - none. I guess Steve & the boys may have had to divest in order to pay some fines. They were showing 25,798 AVNR shares in Q1, but I'm not sorry to see them go.

  • No AVNR holdings. You're sure to see a ton of stories on what the sage of Omaha does hold though. Lots of AMEX, GM, Coke, Exxon, IBM, Proctor & Gamble, USBancorp, Verizon, Wal Mart & Wells Fargo..

1.83+0.04(+2.23%)Aug 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.